Skip to main
TELA

TELA Stock Forecast & Price Target

TELA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TELA Bio is a commercial-stage medical technology company that has recently announced Q4'25 results, which missed top-line estimates but showed improvements on the operating loss side. The company's lowered outlook for 2026 growth is attributed to its own overhaul of its commercial team and go-to-market strategy, but the recent additions of experienced MedTech executives and a solid unit volume growth are positive indicators for future business momentum. The company's capital raise and up-sized debt capacity also provide financial flexibility for its planned expansion and execution. However, consistent execution and stable sales force are crucial for TELA to regain investor confidence and demonstrate its long-term ability to capture market share and generate operational leverage.

Bears say

TELA Bio is facing significant headwinds in the commercialization and sales of its soft-tissue reconstruction solutions, which has led to a significant cut in its sales growth outlook for 2026. Despite a strong product portfolio and growing demand for robotic and laparoscopic procedures, the company's sales team reorganization and high turnover rate among sales representatives have impacted its ability to generate revenue and meet its targets. Additionally, the company's concentrated product portfolio and reliance on reimbursement for healthcare procedures pose significant risks to its future growth and financial stability. With a negative outlook on the company's top-line performance, we believe that TELA Bio's stock is overvalued and are recommending a sell rating for investors.

TELA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TELA Bio, Inc. (TELA) Forecast

Analysts have given TELA a Buy based on their latest research and market trends.

According to 4 analysts, TELA has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TELA Bio, Inc. (TELA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.